UBS Just Upgraded Jazz Pharma to Buy. New $307 Price Target Could Signal a Turning Point
One of Wall Street's major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying.
JAZZ - Jazz Pharmaceuticals plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$255.25
DETAILS
HIGH:
$307.00
LOW:
$229.00
MEDIAN:
$242.00
CONSENSUS:
$255.25
UPSIDE:
6.43%
Stock News
Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except the Dow Jones Industrial Average, which closed 0.32% higher at 49,668, finished the day lower. The small-cap Russell 2000 was the big loser... Here Are Tuesday's Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More
Does Epidiolex Make Jazz Pharmaceuticals a Unique Cannabis Stock?
JAZZ gains unique cannabis exposure through Epidiolex as strong sales growth and patent protection boost long-term visibility.
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
DUBLIN, May 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: 2026 RBC Global Healthcare Conference on Tuesday, May 19, 2026 at 8:00 a.m. ET TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Wednesday, May 27, 2026 at 2:00 p.m.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
International Markets and Jazz (JAZZ): A Deep Dive for Investors
Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
Jazz Pharmaceuticals remains a Strong Buy, with Q1 2026 results affirming robust growth and a successful pivot into oncology. JAZZ's oncology segment, led by Ziihera, Modeyso, and Zepzelca, is driving double-digit sales growth and diversifying away from legacy neuroscience revenues. Ziihera's Priority Review for HER2+ GEA and multiple late-stage trials position JAZZ for significant market expansion and $2B+ peak sales potential via a HER2+ 'pipeline-in-a-product.'
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.34 per share, beating the Zacks Consensus Estimate of $4.67 per share. This compares to earnings of $1.68 per share a year ago.
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
– Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav® revenues grew 18% YoY with 425 net patient adds – – Epidiolex® revenues grew 15% YoY– – Company reaffirms 2026 revenue and expense guidance – DUBLIN, May 5, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2026 (1Q26). "Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026 For U.S. media and investors only DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) containing combinations for the first-line treatment of adult patients with HER2-positive (HER2+) unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or gastroesophageal adenocarcinoma (GEA). The FDA has set a PDUFA target action date of August 25, 2026.
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 first quarter financial results on Tuesday, May 5, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m.
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Rapid oral presentation of PD-L1 subgroup data from HERIZON-GEA-01 evaluating zanidatamab combinations, and additional analyses of tolerability, biomarker response and real-world treatment patterns in HER2+ GEA For U.S. media and investors only DUBLIN, April 21, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present three rapid oral and seven poster presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-June 2, 2026, in Chicago. The data reflect Jazz's continued momentum in oncology and the Company's focus on advancing treatment approaches in difficult-to-treat cancers through late-stage clinical research, real-world evidence and ongoing pipeline innovation.
Assetmark Inc. Buys 5,499 Shares of Jazz Pharmaceuticals PLC $JAZZ
Assetmark Inc. grew its position in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 102.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,848 shares of the specialty pharmaceutical company's stock after purchasing an additional 5,499 shares during the period. Assetmark Inc.'s holdings in Jazz
Choreo LLC Acquires Shares of 2,883 Jazz Pharmaceuticals PLC $JAZZ
Choreo LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund bought 2,883 shares of the specialty pharmaceutical company's stock, valued at approximately $492,000. Several other institutional investors also recently made changes to their
Price Targets
Jazz Pharmaceuticals price target raised to $301 from $232 at Piper Sandler
$301.00
(was $239.40)
Piper Sandler
Jazz Pharmaceuticals initiated with a Market Perform at Bernstein
$229.00
(was $239.40)
Bernstein
Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS
$307.00
(was $229.55)
Ashwani Verma
·
UBS
Jazz Pharmaceuticals price target raised to $245 from $226 at Morgan Stanley
$245.00
(was $224.52)
Sean Laaman
·
Morgan Stanley
Jazz Pharmaceuticals price target raised to $239 from $227 at Raymond James
$239.00
(was $227.88)
Tiago Fauth
·
Raymond James
Jazz Pharmaceuticals price target raised to $252 from $209 at Baird
$252.00
(was $212.26)
Robert W. Baird
Jazz Pharmaceuticals price target raised to $234 from $225 at Barclays
$234.00
(was $212.26)
Etzer Darout
·
Barclays
Jazz Pharmaceuticals price target raised to $225 from $224 at Barclays
$225.00
(was $203.42)
Etzer Darout
·
Barclays
Jazz Pharmaceuticals resumed with an Outperform at Raymond James
$227.00
(was $193.18)
Raymond James
Barclays Reiterates Overweight Rating on Jazz Pharmaceuticals (JAZZ)
$224.00
(was $185.40)
Etzer Darout
·
Barclays
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham
$235.00
(was $161.13)
Ami Fadia
·
Needham
Jazz Pharmaceuticals price target raised to $225 from $205 at Morgan Stanley
$225.00
(was $169.37)
Sean Laaman
·
Morgan Stanley
Jazz Pharmaceuticals price target raised to $219 from $147 at Piper Sandler
$219.00
(was $162.26)
David Amsellem
·
Piper Sandler
Jazz Pharmaceuticals downgraded to Neutral from Buy at UBS
$188.00
(was $176.93)
Ashwani Verma
·
UBS
Jazz Pharmaceuticals price target raised to $194 from $155 at RBC Capital
$194.00
(was $170.14)
RBC Capital
Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
$205.00
(was $170.16)
Sean Laaman
·
Morgan Stanley
Jazz Pharmaceuticals price target raised to $183 from $180 at Morgan Stanley
$183.00
(was $137.97)
Morgan Stanley
Wells Fargo says Avadel settlemnet adds $5 to Jazz Pharmaceuticals DCF
$170.00
(was $137.50)
Wells Fargo
Jazz Pharmaceuticals price target raised to $180 from $167 at Morgan Stanley
$180.00
(was $137.07)
Morgan Stanley
Jazz Pharmaceuticals price target raised to $205 from $200 at Truist
$205.00
(was $124.86)
Joon Lee
·
Truist Financial